sorafenib and Grippe
sorafenib has been researched along with Grippe in 2 studies
Research
Studies (2)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Barclay, W; Frise, R; Gravenstein, I; Herrmann, A; Imai-Matsushima, A; Karlas, A; Lesch, M; Luckner, M; Martin-Sancho, L; Meyer, M; Meyer, TF; Raftery, M; Schönrich, G; Sieben, C; Weege, F; Welke, RW | 1 |
| de Vries, IJ; Desar, IM; Galama, JM; Jacobs, JF; Mulder, SF; Mulders, PF; Olde Nordkamp, MA; Punt, CJ; Teerenstra, S; Torensma, R; van Herpen, CM; Vissers, KC | 1 |
Trials
1 trial(s) available for sorafenib and Grippe
| Article | Year |
|---|---|
Cancer patients treated with sunitinib or sorafenib have sufficient antibody and cellular immune responses to warrant influenza vaccination.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Immunity, Cellular; Immunity, Humoral; Indoles; Influenza Vaccines; Influenza, Human; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Time Factors; Vaccination | 2011 |
Other Studies
1 other study(ies) available for sorafenib and Grippe
| Article | Year |
|---|---|
RNAi-based small molecule repositioning reveals clinically approved urea-based kinase inhibitors as broadly active antivirals.
Topics: A549 Cells; Active Transport, Cell Nucleus; Antiviral Agents; Host-Pathogen Interactions; Humans; Influenza A virus; Influenza A Virus, H5N1 Subtype; Influenza B virus; Influenza, Human; Orthomyxoviridae; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; RNA Interference; RNA Viruses; RNA, Small Interfering; Sorafenib; Urea; Virus Replication | 2019 |